Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AKR1B10P1 is a processed pseudogene of AKR1B10, transcribed as a long non-coding RNA that does not encode a protein but instead regulates gene expression at the RNA level. It is nearly undetectable in normal hepatocytes but highly upregulated in hepatocellular carcinoma cells and tissues. Mechanistically, AKR1B10P1 acts as a competing endogenous RNA by sponging miR-138, thereby stabilizing SOX4 mRNA and promoting epithelial-mesenchymal transition and tumor progression. High levels of AKR1B10P1 RNA are associated with poor prognosis and increased metastasis in HCC but currently have no direct therapeutic targeting or approved drugs.
Functions by acting as a molecular sponge for miR-138, which normally represses SOX4. By competitively binding miR-138, AKR1B10P1 prevents degradation of SOX4 mRNA, resulting in increased SOX4 expression and enhanced EMT and cancer cell aggressiveness
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aldo-keto reductase family 1 member B10 pseudogene 1 (AKR1B10P1).